Valuation: Antengene Corporation Limited

Market Cap 165.05Cr 194.33Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.36TCr 35Cr 244.16Cr 97Cr 1.23TCr 93Cr 91Cr 3.91TCr P/E 2026 *
4.53x
P/E 2027 * -18.5x
Enterprise Value 165.05Cr 194.33Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.36TCr 35Cr 244.16Cr 97Cr 1.23TCr 93Cr 91Cr 3.91TCr EV / Sales 2026 *
1.99x
EV / Sales 2027 * 4.89x
Free-Float
62.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 week-6.30%
Current month-18.35%
1 month-15.92%
3 months-32.58%
6 months-44.28%
Current year-25.46%
1 week 2.7
Extreme 2.705
3.02
1 month 2.7
Extreme 2.705
3.54
Current year 2.7
Extreme 2.705
6.28
1 year 2.7
Extreme 2.705
6.28
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
13.06
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 28/08/2018
Chief Tech/Sci/R&D Officer 42 20/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 60 28/08/2018
Director/Board Member 51 09/11/2020
Director/Board Member 59 14/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/09/26 Other

Director

2,00,000 0.0294%
10/09/26 Other 20,00,000 0.2944%
10/09/26 Other

Director

2,00,000 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-6.30%-42.58%+124.21% 25Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+0.98%+2.68%+12.25%+83.90% 5.55TCr
+1.75%+2.01%+13.30%+105.71% 5.3TCr
-1.80%-1.80%+25.47%+54.27% 4.6TCr
-0.66%-3.37%+17.32%+97.94% 4.25TCr
+0.50%+0.26%+224.35%+925.53% 4.04TCr
-0.26%-4.20%+10.86%+45.18% 3.23TCr
-2.07%+42.73%+103.77%+90.26% 3.45TCr
-2.72%-8.79%+22.58%-5.63% 2.42TCr
Average -0.49%+2.86%+42.47%+158.24% 3.93TCr
Weighted average by Cap. -0.23%+3.13%+48.96%+159.72%

Financials

2026 *2027 *
Net sales 83Cr 98Cr 12Cr 11Cr 10Cr 9.32Cr 17Cr 1.19TCr 18Cr 122.83Cr 49Cr 620.93Cr 47Cr 46Cr 1.97TCr 34Cr 40Cr 5.07Cr 4.54Cr 4.19Cr 3.79Cr 7.09Cr 482.56Cr 7.2Cr 50Cr 20Cr 252.55Cr 19Cr 19Cr 799.89Cr
Net income 33Cr 39Cr 5Cr 4.48Cr 4.13Cr 3.74Cr 6.99Cr 476.18Cr 7.11Cr 49Cr 20Cr 249.21Cr 19Cr 18Cr 789.3Cr -8.48Cr -9.98Cr -1.27Cr -1.14Cr -1.05Cr -95.14L -1.78Cr -121.15Cr -1.81Cr -13Cr -5Cr -63Cr -4.77Cr -4.67Cr -200.82Cr
Net Debt - -
Projected Income Statement - Annual - Antengene Corporation Limited
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
122
Date Price Change Volume
29/26/29 HK$2.825 -0.53% 2,82,000
28/26/28 HK$2.840 +2.34% 10,49,500
27/26/27 HK$2.775 -5.61% 10,96,500
26/26/26 HK$2.940 +1.91% 3,38,000
23/26/23 HK$2.885 +1.58% 8,29,000
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.399CNY
Average target price
4.150CNY
Spread / Average Target
+72.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited
  1. Stock Market
  2. Stocks
  3. 6996 Stock